

MEDCAP INVESTOR IN LIFE SCIENCE

Company Presentation 2025

We create value in Life Science and contribute to improved quality of life









Strategy Buy & Build A long-term home for well run Life Science companies


> EBITA CAGR 5 years






Sales and EBITA rolling 12 months by quarter

The Group's net sales LTM (MSEK) excluding one-time effects



The Group's EBITDA and EBITA (line) LTM (MSEK) excluding one-time effects







MedCap | An active investor in Life Science companies

Last Twelve Months, Q4 2024

Sales by Business Area



Sales by Market





Our Model

- Life Science

Sector focus Network of expertise Knowledge sharing Market insight



-Entrepreneurship

Decentralized & local responsibility Integrity of acquired brands Quick & agile, yet long-term mindset Ambitious organic business plans Group Scale

Scalable business areas Merger & Acquisitions Governance – ESG Financing



Success factors


Solid markets	Understanding the eco-systems					Active ownership	
Non-cyclical	Payor	or Prescriber		End-user		People & Management	
Demographic drivers	Healthcare	Healthcare providers		Distribution		Business objectives	
Market nisches	Regulatior	Regulation Sal		les & Marketing		Performance management	
Market share potential	Product D	Product Development		Offering		Bolt-on acquisitions	




Examples of healthcare trends relevant to our business

	Assistive Tech	MedTech	Specialty Pharma	
Consumer Health				
Health Economics & Regulations and Requirements				
Pharmaceutical shortages				
Screening, Diagnostic				
Digitalization, Connectivity, Use of data				
Home care, Telemedicine, Remote Monitoring				
Prevalence of Diagnoses & Chronic Conditions				
Demographics & Aging Population				
DCAD INVESTOR				l

MedCap Business Areas







Investment strategy

Scope

Life Science Assistive | MedTech | Pharma


> **Europe** Add-ons globally

Small / Mid-size Businesses Sales <50 mEUR

> Majority Owner 51-100% Ownership


Long-term Buy & Build | No exit horizon








Financial Targets






Financial Targets










How we track our financial targets in our businesses

Financial Objectives	Key Metrics In Our Businesses				
>15% EBITA growth (CAGR)	Organic and acquisition driven sales growth (depending on maturity of business) Profit margins				
Return on Equity >20%	Core Working Capital / Sales, Cash Conversion, EBITA / (Fixed assets & WC Capex IRR, Pay-back Acquisition valuation				
Net debt / EBITDA <3	Group level				
Grow size of business	Sales growth Business development pipeline M&A Pipeline				



Sales and EBITA rolling 12 months by quarter



Net sales

EBITA R12

Excluding one-time effects



Why MedCap?

Sustainable Industry

Life Science industry improves quality of life

MedCap's portfolio companies contributes to inclusion, care and healthcare

We strive to operate sustainable and work towards UN's sustainable development goals



Profitable Growth

2

Annual growth of 19% over the last 5 years

Average EBITA growth of 23% over the last 5 years

Financial targets and capacity to grow

Objective to grow both organic and by acquisitions

3

Proven & Scalable Model

Decentralized model – customer focused responsibility and decisions making

Combination of entrepreneurial drive in smaller companies and the strength of a larger group

Long-term value creation



4

Large & Growing Market

Fragmented market – many small and medium sized life science companies in Europe

Growing market – demographics as well as healthcare investments and innovation drives growth

Good possibilities for acquisitions



Thank You !





Anders Dahlberg CEO anders.dahlberg@medcap.se +46 704 269 262



Kristina Ekblad CFO kristina.ekblad@medcap.se +46 703 322 167

